Lisata Therapeutics (LSTA) is entering a pivotal, data-rich period with several clinical milestones on the horizon. The company has strengthened its position through a global license agreement with Catalent to integrate certepetide into the SMARTag ADC platform and a strategic alliance with GATC Health to leverage AI-powered drug discovery. With multiple ongoing trials showcasing certepetide's potential to boost the effectiveness of chemotherapy, immunotherapy, and ADCs, and a cash runway secured into early 2027 with no debt, Lisata is well-positioned for meaningful progress in the near term.
Company Overview
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.